CAS 52328-98-0|Dimethylcurcumin
Introduction：Basic information about CAS 52328-98-0|Dimethylcurcumin, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Dimethylcurcumin | ||
|---|---|---|---|
| CAS Number | 52328-98-0 | Molecular Weight | 396.433 |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 588.6±50.0 °C at 760 mmHg |
| Molecular Formula | C23H24O6 | Melting Point | 129-130 °C |
| MSDS | / | Flash Point | 201.8±23.6 °C |
Names
| Name | (1E,4Z,6E)-1,7-Bis(3,4-dimethoxyphenyl)-5-hydroxy-1,4,6-heptatrie n-3-one |
|---|---|
| Synonym | More Synonyms |
Dimethylcurcumin BiologicalActivity
| Description | ASC-J9 is an androgen receptor degradation enhancer that effectively suppresses castration resistant prostate cancer cell proliferation and invasion. |
|---|---|
| Related Catalog | Signaling Pathways >>Others >>Androgen ReceptorResearch Areas >>Cancer |
| In Vitro | ASC-J9 is able to degrade fAR and AR3 in a dose-dependent manner in various human PCa cells. ASC-J9 can also effectively suppress AR-targeted genes in CWR22Rv1-fARKD cells. ASC-J9 (5 or 10 µM) significantly suppresses the DHT-induced cell growth in all three PCa cell lines. ASC-J9 suppresses AR-targeted genes and cell growth by degradation of fAR and ectopic AR3 in C81 and C4-2 cells[1]. ASC-J9 selectively promotes AR degradation by disrupting the interaction between AR and AR coregulators. ASC-J9 reduces the AR aggregated AR-112Q in cells. ASC-J9 suppresses the aggregation of AR-112Q in SBMA PC12/AR-112Q cells[2]. |
| In Vivo | ASC-J9 (75 mg/kg, i.p.) degrades both fAR and AR3 in the xenografted tumors in vivo, and SC-J9-treated tumors has significantly decreased Ki67-positive cells[1]. ASC-J9 (50 mg/kg every 48 h, i.p.) substantially ameliorates the SBMA symptoms in AR-97Q mice, and ameliorates neuromuscular pathological findings. The ASC-J9-treated SBMA mice have relatively normal serum testosterone concentrations[2]. ASC-J9-treated mice show significantly smaller prostate tumor sizes when compared with those receiving classic ADT/castration with little serum androgen[3]. |
| Cell Assay | For the cell survival assay, the PC12/AR-112Q and PC12/AR-10Q cells are cultured as described previously and incubated cells in the presence of 10 μg/mL doxycycline for 24 h. Then the cells are treated with vehicle, 5 μM ASC-J9 or 10 μM ASC-J9, along with 1 nM DHT, and determined cell viability using Trypan blue staining at specific time intervals. |
| Animal Admin | CWR22Rv1 cells (1×106 cells per site) are injected into both anterior prostates of castrated nude mouse after 2 weeks of implantation. The mice are randomLy divided into two groups (four mice/eight tumors each group) and either receives 75 mg/kg ASC-J9 intraperitoneal injection or vehicle control every other day. After 4 weeks of treatment, all mice are killed to examine the tumor growth. Body weights and mice activity are measured weekly. |
| References | [1]. Yamashita S, et al. ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Neoplasia. 2012 Jan;14(1):74-83. [2]. Yang Z, et al. ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor.Nat Med. 2007 Mar;13(3):348-53. [3]. Lee SO, et al. New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs non-stem/progenitor cells. J Mol Cell Biol. 2012 Jul 24. [4]. Ma W, et al. Targeting androgen receptor with ASC-J9 attenuates cardiac injury and dysfunction in experimental autoimmune myocarditis by reducing M1-like macrophage. Biochem Biophys Res Commun. 2017 Apr 15;485(4):746-752. doi: 10.1016/j.bbrc.2017.02.123. Epub 2017 Feb 27. |
Chemical & Physical Properties
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 588.6±50.0 °C at 760 mmHg |
| Melting Point | 129-130 °C |
| Molecular Formula | C23H24O6 |
| Molecular Weight | 396.433 |
| Flash Point | 201.8±23.6 °C |
| Exact Mass | 396.157288 |
| PSA | 74.22000 |
| LogP | 4.05 |
| Vapour Pressure | 0.0±1.7 mmHg at 25°C |
| Index of Refraction | 1.608 |
| InChIKey | ZMGUKFHHNQMKJI-CIOHCNBKSA-N |
| SMILES | COc1ccc(C=CC(=O)C=C(O)C=Cc2ccc(OC)c(OC)c2)cc1OC |
Synonyms
| ASC-J9 |
| (1E,4Z,6E)-1,7-Bis(3,4-dimethoxyphenyl)-5-hydroxy-1,4,6-heptatrien-3-one |
| (1E,4Z,6E)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one |
| 1,4,6-Heptatrien-3-one, 1,7-bis(3,4-dimethoxyphenyl)-5-hydroxy-, (1E,4Z,6E)- |
| Dimethylcurcumin |
